SUVEN PHARMACEUTICALS
Quarterly Results Analysis [Dec2023]
SUVEN PHARMACEUTICALS Quarterly Results
Consolidated | Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 Audited |
Dec2022 UnAudited |
Sep2022 UnAudited |
Jun2022 UnAudited |
Mar2022 Audited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹220 Cr | ₹231 Cr | ₹348 Cr | ₹369 Cr | ₹354 Cr | ₹278 Cr | ₹339 Cr | ₹364 Cr |
Expenses | ₹155 Cr | ₹133 Cr | ₹181 Cr | ₹200 Cr | ₹207 Cr | ₹179 Cr | ₹188 Cr | ₹207 Cr |
Operating Income | ₹65 Cr | ₹98 Cr | ₹167 Cr | ₹169 Cr | ₹147 Cr | ₹100 Cr | ₹151 Cr | ₹157 Cr |
Other Income | ₹14 Cr | ₹20 Cr | ₹11 Cr | ₹11 Cr | ₹13 Cr | ₹11 Cr | ₹11 Cr | ₹17 Cr |
Interest | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr | ₹1 Cr | ₹0 Cr | ₹1 Cr | ₹2 Cr |
Depreciation | ₹13 Cr | ₹12 Cr | ₹13 Cr | ₹12 Cr | ₹12 Cr | ₹12 Cr | ₹12 Cr | ₹10 Cr |
Profit Before Tax | ₹65 Cr | ₹105 Cr | ₹164 Cr | ₹166 Cr | ₹146 Cr | ₹98 Cr | ₹149 Cr | ₹161 Cr |
Profit After Tax | ₹47 Cr | ₹80 Cr | ₹121 Cr | ₹124 Cr | ₹108 Cr | ₹72 Cr | ₹108 Cr | ₹92 Cr |
EPS | ₹1.84 | ₹3.13 | ₹4.74 | ₹4.87 | ₹4.23 | ₹2.83 | ₹4.22 | ₹3.60 |
Industry Peers & Returns | 1W | 1M | 1Y |
SUVEN PHARMACEUTICALS | 5.1% | -3.2% | 38.4% |
SUN PHARMACEUTICAL INDUSTRIES | 3% | 2.3% | 68.2% |
CIPLA | 2.5% | 0.4% | 71.7% |
DR REDDYS LABORATORIES | -0.2% | -4.9% | 40.3% |
ZYDUS LIFESCIENCES | 5% | 10.4% | 109.1% |
DIVIS LABORATORIES | -1.6% | -7% | 23.8% |
MANKIND PHARMA | NA | NA | NA |
TORRENT PHARMACEUTICALS | 2.9% | -2.2% | 69% |
LUPIN | 2.8% | 0% | 147.8% |
SUVEN PHARMACEUTICALS Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -4.86 % |
Y-o-Y | -37.86 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Dec2023 | ₹220 Cr | -4.86 | |
Sep2023 | ₹231 Cr | -33.52 | |
Jun2023 | ₹348 Cr | -5.90 | |
Mar2023 | ₹369 Cr | 4.41 | |
Dec2022 | ₹354 Cr | 27.07 | |
Sep2022 | ₹278 Cr | -17.83 | |
Jun2022 | ₹339 Cr | -6.88 | |
Mar2022 | ₹364 Cr | - |
SUVEN PHARMACEUTICALS Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | -33.50 % |
Y-o-Y | -55.59 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Dec2023 | ₹65 Cr | -33.50 | |
Sep2023 | ₹98 Cr | -41.33 | |
Jun2023 | ₹167 Cr | -1.25 | |
Mar2023 | ₹169 Cr | 15.26 | |
Dec2022 | ₹147 Cr | 46.87 | |
Sep2022 | ₹100 Cr | -33.80 | |
Jun2022 | ₹151 Cr | -3.91 | |
Mar2022 | ₹157 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -30.09 % |
Y-o-Y | -28.53 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Dec2023 | 29.64% | -30.09 | |
Sep2023 | 42.4% | -11.74 | |
Jun2023 | 48.04% | 4.94 | |
Mar2023 | 45.78% | 10.39 | |
Dec2022 | 41.47% | 15.58 | |
Sep2022 | 35.88% | -19.43 | |
Jun2022 | 44.53% | 3.17 | |
Mar2022 | 43.16% | - |
SUVEN PHARMACEUTICALS Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | -41.24 % |
Y-o-Y | -56.60 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Dec2023 | ₹47 Cr | -41.24 | |
Sep2023 | ₹80 Cr | -34.02 | |
Jun2023 | ₹121 Cr | -2.73 | |
Mar2023 | ₹124 Cr | 15.09 | |
Dec2022 | ₹108 Cr | 49.49 | |
Sep2022 | ₹72 Cr | -33.00 | |
Jun2022 | ₹108 Cr | 17.32 | |
Mar2022 | ₹92 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | -38.22 % |
Y-o-Y | -30.15 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Dec2023 | 21.27 % | -38.22 | |
Sep2023 | 34.43 % | -0.78 | |
Jun2023 | 34.7 % | 3.40 | |
Mar2023 | 33.56 % | 10.21 | |
Dec2022 | 30.45 % | 17.66 | |
Sep2022 | 25.88 % | -18.46 | |
Jun2022 | 31.74 % | 26.00 | |
Mar2022 | 25.19 % | - |
SUVEN PHARMACEUTICALS Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | -41.21 % |
Y-o-Y | -56.50 % |
Quarters | EPS | % Change | |
---|---|---|---|
Dec2023 | ₹1.84 | -41.21 | |
Sep2023 | ₹3.13 | -33.97 | |
Jun2023 | ₹4.74 | -2.67 | |
Mar2023 | ₹4.87 | 15.13 | |
Dec2022 | ₹4.23 | 49.47 | |
Sep2022 | ₹2.83 | -32.94 | |
Jun2022 | ₹4.22 | 17.22 | |
Mar2022 | ₹3.6 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD